NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions.
The completion of this offering will provide NanoViricides with additional working capital to advance its clinical-stage broad-spectrum antiviral drug, NV-387. NV-387 has been granted Orphan Drug Designation by the U.S. FDA Office of Orphan Products Development, which could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. The drug targets a range of respiratory viral illnesses and has shown efficacy in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles. According to the company, NV-387 is designed to be a first-visit treatment for patients presenting with respiratory viral infections.
The offering underscores investor confidence in NanoViricides' approach, which utilizes host-mimetic nanomedicine technology that viruses and their variants cannot escape. This technology aims to provide broad-spectrum antiviral coverage, addressing a critical need in the face of emerging viral threats. The proceeds from the offering will likely be used to further clinical trials and regulatory processes, bringing NV-387 closer to potential market approval.
For more details on the offering, the full press release is available at https://ibn.fm/Z8Etj. Additional information about NanoViricides can be found in the company's newsroom at https://ibn.fm/NNVC.
The successful pricing of this offering is a significant step for NanoViricides as it continues to develop its pipeline of antiviral candidates. With the ongoing threat of respiratory viruses and the potential for future pandemics, the advancement of broad-spectrum antivirals like NV-387 is of global importance. The company's focus on a technology that viruses cannot easily evade positions it as a key player in the fight against viral diseases.
